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Vitamin ARetinoic acid (atRA) signaling is essential for regulating embryonic development, and atRA levels must be
tightly controlled in order to prevent congenital abnormalities and fetal death which can result from both
excessive and insufﬁcient atRA signaling. Cellular enzymes synthesize atRA from Vitamin A, which is obtained
from dietary sources. Embryos express multiple enzymes that are biochemically capable of catalyzing the
initial step of Vitamin A oxidation, but the precise contribution of these enzymes to embryonic atRA synthesis
remains unknown. Using Rdh10trex-mutant embryos, dietary supplementation of retinaldehyde, and retinol
dehydrogenase (RDH) activity assays, we demonstrate that RDH10 is the primary RDH responsible for the ﬁrst
step of embryonic Vitamin A oxidation. Moreover, we show that this initial step of atRA synthesis occurs
predominantly in a membrane-bound cellular compartment, which prevents inhibition by the cytosolic
cellular retinol-binding protein (RBP1). These studies reveal that widely expressed cytosolic enzymes with
RDH activity play a very limited role in embryonic atRA synthesis under normal dietary conditions. This
provides a breakthrough in understanding the precise cellular mechanisms that regulate Vitamin A
metabolism and the synthesis of the essential embryonic regulatory molecule atRA.BSEB 328B, Oklahoma City, OK
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olaeva@ouhsc.edu
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The Vitamin A derivative, all-trans retinoic acid (atRA), is a potent
signaling molecule necessary for patterning, morphogenesis, and
organogenesis during embryonic development (Clagett-Dame and
DeLuca, 2002; Duester, 2008; Ross et al., 2000; Zile, 1998). The level
and tissue distribution of atRA must be tightly regulated during
embryogenesis as excessive or insufﬁcient atRA signaling can cause a
variety of congenital abnormalities and fetal death (Clagett-Dame and
DeLuca, 2002; Duester, 2008; Ross et al., 2000; Zile, 1998). During
embryogenesis the precise regulation of atRA levels and tissue
distribution are accomplished through a balance of synthesis and
degradation. Because atRA signaling controls transcription of numer-
ous essential developmental genes, it is important to gain a clear
understanding of the enzymes, binding proteins and cellular condi-
tions that impact the metabolism of this essential compound.Synthesis of atRA from its precursor Vitamin A (all-trans-retinol;
atROL) occurs in a two-step process. First, atROL is oxidized to
generate all-trans-retinal (atRAL), a reaction facilitated by an enzyme
with retinol dehydrogenase (RDH) activity. Once atRAL is generated,
it is subsequently oxidized to form retinoic acid, a reaction facilitated
by an enzyme with retinaldehyde dehydrogenase (RALDH) activity.
RALDH activity is known to be mediated by the three members of the
RALDH family, RALDH1, RALDH2, and RALDH3 (Niederreither et al.,
1997, 2002a). Each of the RALDH enzymes is expressed in a distinct
spatiotemporal pattern during embryogenesis and is required for
synthesis of atRA in distinct tissues. RALDH2 is the most widely
expressed of the RALDHs, and is most crucial for embryonic atRA
synthesis, as Raldh2−/− embryos die around E10.5 and lack axial
rotation, neural tube closure, heart looping and cardiac atrial chamber
formation (Niederreither et al., 1999). Raldh1−/−mice exhibit normal
survival to adulthood, are fertile, and exhibit no obvious defects (Fan
et al., 2003). Raldh3−/−mice exhibit mild ocular defects and lethality
at birth due to a blockage of the nasal passages, which prevents
efﬁcient respiration (Dupe et al., 2003).
Whereas the enzymes responsible for the RALDH oxidation of
atRAL to atRA have been deﬁnitively known for some time, the
identity of the enzymes essential for the oxidation of Vitamin A
(atROL) to atRAL during embryogenesis has remained elusive.
Biochemically, members of two large enzyme families are capable of
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drogenase/reductases (SDR) and the cytosolic medium-chain alcohol
dehydrogenases (ADH) (Duester, 2008; Pares et al., 2008). Because
several ADHs are widely or ubiquitously expressed during embryo-
genesis it was originally proposed that the initial oxidation of Vitamin
A during retinoic acid synthesis was carried out ubiquitously by ADH
family members (Ang et al., 1996a,b; Duester et al., 2003; Molotkov
et al., 2002). However, our recent ﬁnding that a point mutation in
Rdh10 (Rdh10trex) impairs RA synthesis and causes numerous embry-
onic abnormalities resulting in embryonic lethality between E10.5
and E13.0 demonstrates clearly that RDH10 plays a predominant role
in the ﬁrst reaction of the two-step process of atRA synthesis (Sandell
et al., 2007). The phenotype of the Rdh10trexmutant is consistent with
the known phenotypes of retinoid deﬁciency, although not quite as
severe as the phenotype of Raldh2−/− embryos. This is likely due to
the reduced enduring level of atRA produced in the Rdh10trex mutant
embryos, which may result from RDH activity of other enzymes or
from residual activity of the destabilized RDH10 protein produced by
the point mutation.
RDH10 and ADH familymembers could each conceivably contribute
to embryonic Vitamin A metabolism. RDH10 is expressed in a
spatiotemporally restricted pattern within the embryo, coinciding
closely with sites of RALDH gene expression (Cammas et al., 2007;
Romand et al., 2008; Sandell et al., 2007). ADH1 (a class I enzyme) and
ADH7(aclass IVenzymewith robust RDHactivity in vitro) areexpressed
in distinct tissue-speciﬁc patterns in mouse embryos while ADH5 (a
class III ADH enzymewith lowRDH activity) is found broadly expressed
throughout the embryo (Duester et al., 1995; Molotkov et al., 2002).
Given that RDH10 and ADH family members are each present within
embryonic tissues and are each capable of RDH activity in vitro, we
sought to understand why ADHs have little or no physiologically
relevant RDH activity in embryos and what distinguishes RDH10,
making it thedominantRDH in atRAmetabolismduring embryogenesis.
The precise enzymatic role of RDH10 in embryonic atRA synthesis
has not been fully demonstrated, although our previous work showed
that RDH10 catalyzes the oxidation of atROL to atRAL in vitro (Wu
et al., 2002). Since that reaction is the ﬁrst step of atRA synthesis, and
Rdh10trex mutants have a deﬁciency in atRA synthesis, we proposed
that RDH10 is necessary to produce sufﬁcient levels of atRAL to serve
as substrate for RALDH enzymes that catalyze the second step of atRA
synthesis. However, it was surprising that the widely expressed ADHs,
which have RDH activity, did not compensate for the loss of RDH10.
The inability of ADHs to compensate for the loss of RDH10 could
indicate that ADHs do not normally function in the capacity of an RDH
in vivo despite in vitro evidence to the contrary. An alternative
explanation could be that RDH10 is essential for both the ﬁrst and
second oxidative steps of atRA synthesis. Although SDRs and ALDHs
utilize completely distinct modes of catalysis and the alcohol
oxidation is chemically reversible, whereas aldehyde oxidation is
not, we decided to systematically explore all possible developmental
reasons behind the embryonic requirement for RDH10. Thus, in order
to fully explore theprecise enzymatic activity of RDH10 itwasnecessary
to determine the capacity of RDH10 to catalyze the oxidation of atRAL.
The importance of resolving the precise role of RDH10 in embryonic
atRA synthesis is underscored by studies in RARE-lacZ reporter mice
that have indicated that there are sites of RALDH-independent atRA
synthesis in the developing embryo, which include areas in the
forebrain, hindbrain, spinal cord, neural tube and heart (Mic et al.,
2002; Niederreither et al., 2002b). Such areas of “RALDH-independent”
activity could be accounted for by unidentiﬁed RALDH(s). Alternatively,
several studies have identiﬁed non-RALDH enzymes with the capability
of synthesizing atRA in vitro, including members of the Cytochrome
P450 (CYP) family (CYP1A1, CYP1A2, CYP3A6, and CYP1B1) (Chambers
et al., 2007; Ding et al., 2001; Roberts et al., 1992; Tomita et al., 1993,
1996), and these enzymes may account for RALDH-independent atRA
synthesis. CYP1B1 is particularly interesting, because it possesses theunique enzymatic capacity to catalyze the stepwise oxidation of atROL
to atRA in vitro, and thus combines the function of a RDH and a RALDH
into one enzyme (Chambers et al., 2007). However, it remains to be
determined if CYP1B1 can directly synthesize atRA from atROL in vivo.
The CYP enzymes generally have much lower activity than the RALDHs,
but they may contribute to sites of RALDH-independent atRA synthesis
during embryogenesis. Most interestingly, RDH10 is expressed in at
least two areas which have RALDH-independent atRA synthesis,
including the ﬂoor plate of the neural tube and the hindbrain (Romand
et al., 2008; Sandell et al., 2007), raising the possibility that RDH10may
contribute to RALDH-independent atRA synthesis, either on its own or
in concert with CYPs.
Another aspect of atRA metabolism that is not well understood is
the sub-cellular location of various reactions and intermediates. The
precursor molecule atROL is derived initially from the maternal diet,
distributed to the embryo through the circulation and transported
into embryonic cells via the cell surface receptor STRA6 (Bouillet et al.,
1997; Kawaguchi et al., 2007). The second reaction in atRA synthesis,
the conversion of atRAL to atRA by the RALDH family of enzymes takes
place in the cytosol. Thus, it is reasonable to expect that the initial RDH
reaction, the conversion of atROL to atRAL, would also occur within
the cytosol. However, the ﬁnding that RDH10, which is membrane-
bound, is the dominant embryonic RDH, and the fact that ADHs, which
are cytosolic, do not apparently contribute substantially to the
process, led us to hypothesize that the ﬁrst enzymatic step of atRA
synthesis occurs not in the cytosol but, instead, takes place primarily
in a membrane compartment. We therefore sought to deﬁne the sub-
cellular location of the ﬁrst step of atRA synthesis and determine the
relative contribution of ADHs and RDH10 to this important process.
In the present study we investigated the role of RDH10 in the
stepwise synthesis of atRA during embryogenesis. We demonstrated
that RDH10 does not catalyze conversion of atRAL to atRA in vitro and
rescued Rdh10trex mutants by supplementation of the maternal diet
with atRAL. Taken together these data demonstrate that RDH10 is
essential only for the ﬁrst step of embryonic atRA synthesis. We
measured total embryonic RDH activity and showed that membrane-
bound RDH activity is abolished in Rdh10trex mutants, demonstrating
that RDH10 is the primary enzyme carrying out RDH activity in the
membrane compartment within embryos.
We show that RDH10 is unable to oxidize atROL bound to the
cytosolic cellular retinol-binding protein (RBP1) in vitro anddemonstrate
this inhibitory protein is expressed during the stages of development
when RDH10 is active. We also demonstrate that ADH7, which exhibits
high RDH activity on atROL in aqueous solution, is unable to oxidize
atROL that has been incorporated into liposomes. Taken together, these
data suggest that RDH10 oxidizes a RBP1-free pool of atROL present in
cellular membranes in vivo, and that the ADH enzymes are unable to
easily accessmembrane pools of atROL. Thus, we speculate that ADHs do
not contribute to embryonic synthesis of atRA because theymay function
only in the aqueous cytosolic compartment where inhibitory RBP1 is
present. Importantly, the data indicate that the ﬁrst step in the two-step
embryonic atRA synthesis is carried out predominantly by RDH10 in a
membrane-bound environment protected from inhibitory RBP1.
Materials and methods
Construction of expression vectors
AhumanRALDH2mammalian expressionvectorwas constructed by
PCR ampliﬁcation from a commercially-available RALDH2 cDNA clone
(CLONE ID 30471325, Open Biosystems, Huntsville, AL) using the
following primers: forward, 5′-ATGGATCCGCCACCATGGCCTCGCTG-
CAGCTC-3′ containing a BamHI site (underline) and reverse, 5′-
ACGAATTCGGAGTTCTTCTGGGGGATCTTCA-3′ containing an EcoRI site
(underline). The PCR product was digested with BamHI and EcoRI and
inserted into the pcDNA6/V5/His mammalian expression vector
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The bacterial expression vector pQE30-CRBP-His was kindly provided
by Dr. Kris Palczewski at Case Western Reserve University, and the
bacterial expression vector pet19b-CRALBP-His was a kind gift from
Dr. John Crabb at the Cleveland Clinic Foundation (Crabb et al., 1998).
The pcDNA6-RDH10 mammalian expression vector was described
previously (Takahashi et al., 2009; Wu et al., 2002).
A human ADH7 full-length mammalian expression vector was
constructed by PCR ampliﬁcation from a commercially available ADH7
cDNA clone corresponding to NCBI reference sequence NM_000673
(CLONE ID LIFESEQ3287393, Open Biosystems, Huntsville, AL) using the
following primers: forward, 5′-TACAAAGACGATGACGACAAGATGGG-
CACTGCTGGAAAAG-3′ containing a partial Flag tag sequence (italic)
and reverse, 5′-ACGAATTCTCAAAACGTCAGGACCGTTCGAATG-3′ con-
taining and EcoRI site (underline). After the ﬁrst PCR ampliﬁcation, the
ADH7 PCR product was inserted into a pGEM-TEasy vector (Promega)
by TA cloning. Then a second PCR was performed using the original
reverse primer and a new forward primer in order to add residues of the
Flag tag and a BamHI site: forward, 5′-AAGGATCCGCCACCATGGACTA-
CAAAGACGATGACGACAAG-3′ containing a BamHI site (underline) and a
full Flag tag sequence (italic). Then the PCR product was digested with
BamHI and EcoRI and inserted into the pcDNA3.1 (+) mammalian
expression vector (Invitrogen, Carlsbad, CA, U.S.A.) to express ADH7
with an N-terminal Flag tag.
In vitro RALDH activity assays
Whole cell lysates were prepared after COS1 cells were either
transiently transfected with either pcDNA6-RDH10 or pcDNA6-
RALDH2-His expression vectors using FuGENE 6 reagent (Roche,
Indianapolis, IN, U.S.A.). At 48 h after transfection, cells were lysed by
sonication in either RDH activity buffer (0.1 M sodium phosphate pH
7.4) or RALDH activity buffer (20 mMHEPES pH 8.5 with 150 mMKCl,
1 mM EDTA and 2 mM DTT) and stored at −80 °C.
All the following procedureswere performedunder dim red light. To
measure RALDH activity in vitro, the whole cell lysates of COS1 cells
expressing either recombinant RDH10 or RALDH2were used as a source
of the enzymes.A total of 200 μgof cell lysateproteinwas suspended in a
ﬁnal volume of 200 μl of either RDH activity buffer or RALDH activity
buffer containing 0.5% BSA, and 2 mM nicotinamide adenine dinucle-
otide (NAD+) or nicotinamide adenine dinucleotide phosphate
(NADP+). The reaction was initiated by adding 2 μl of atRAL dissolved
in DMF (dimethyl formamide) at a ﬁnal concentration of 5 μM. The
reaction mixtures were incubated at 37 °C for 30 min with gentle
agitation. The reaction was terminated by the addition of 200 μl of
methanol. To extract non-polar retinoids, 4 μl of 0.1 M sodium
hydroxide was added followed by 600 μl of hexane. After removal of
non-polar retinoids, retinoic acid was extracted by the addition of 16 μl
of 5 M HCl and 600 μl of hexane. Samples were then dried under argon
and dissolved inmethanol for high performance liquid chromatography
(HPLC) analysis (Waters 515 HPLC pump and 2996 Photodiode Array
Detector; Waters Corporation, Milford, MA) using a reverse phase
3.5 μm column (Waters C18; Waters Corporation, Milford, MA).
Retinoids were separated by a gradient of 50% to 100% methanol in
water plus 0.1% triﬂuoroacetic acid. The peak of each retinoid isomer
was identiﬁed based on its absorption spectrum and retention time on
the column compared to pure retinoid standards. The enzymatic activity
was calculated from the area of the atRA peak using synthetic puriﬁed
atRA as a standard for calibration with Empower software (Waters
Corporation, Milford, MA). Kinetic parameters were calculated using
EnzFitter program (Biosoft, Cambridge, UK).
Rescue of Rdh10trex-mutant embryos with atRAL supplementation
Timed matings were performed to deﬁne E0 as 12:00 a.m. of the
morning when a mating semen plug was observed. For rescuesexperiments, atRAL was dissolved in corn oil and administered
approximately every 12 hours by oral gavage to pregnant females
from E7.25 up to E12.25 at a ﬁnal concentration of 12.5 mg atRAL/kg
maternal body weight. Mock-gavaged animals received corn oil alone,
and all gavage doses were given at a volume of 100 μl. Embryos were
collected at various stages and genotyped to identify the Rdh10trex
allele pointmutation as described previously (Sandell et al., 2007). For
morphological analyses, embryos were ﬁxed in 10% neutral buffered
formalin, embedded in parafﬁn, sectioned and stained with hema-
toxylin and eosin. Alcian blue cartilage staining and β-galactosidase
staining of embryos were performed as previously described (Sandell
et al., 2007).
Embryonic RDH activity assays
Whole embryos were resuspended in 4 volume equivalents of
0.1 M sodium phosphate pH 7.4 with 0.25 M sucrose and homoge-
nized by sonication. Lysates were centrifuged at 10,000×g for 10 min
to remove cell debris. The supernatant was centrifuged at 100,000×g
for 1 h to separate cytosolic and membrane fractions. The pellet
(membranes) was resuspended in RDH activity buffer, analyzed for
protein concentration by Bradford analysis, and frozen at−80 °C until
time of analysis.
Under dim red light, a total of 25 μg or 50 μg of embryo membrane
proteins were suspended in a ﬁnal volume of 200 μl of RDH activity
buffer containing 1% BSA, and 1 mMNAD+ or NADP+. The reactionwas
initiated by adding 2 μl of 11,12-3H-atROL (1 mCi/ml, 52 Ci/mmol,
PerkinElmer) dissolved in DMF at a ﬁnal concentration of 0.2 μM. After
incubation at 37 °C for 1 h with gentle agitation, the reaction was
terminated by the addition of 300 μl of methanol, and retinoids were
extractedwith 300 μl of hexane for normal phaseHPLC analysis coupled
to Radiomatic 610TR Flow Scintillation Analyzer (PerkinElmer). The
peak of each retinoid isomer was identiﬁed based on the retention time
on the column compared to pure retinoid standards, and enzymatic
activity was calculated from the area of the 3H-atRAL peak using
synthetic puriﬁed 3H-atRAL as a standard for calibration with Radio-
matic 610TR software.
Nickel-afﬁnity chromatography
Bacterial cells expressing Rbp1-His were suspended in cell lysis
buffer (50 mM NaH2PO4, 300 mM NaCl pH 8.0) supplemented with
1 mM PMSF, 25 μg/ml of aprotinin, leupeptin, and pepstatin, and
10 μg/ml DNase and sonicated on ice. The cell lysates were incubated
with Ni resin for 2 h at 4 °C. After adsorption, unbound proteins were
removed, and the beads were washed with cell lysis buffer containing
20 mM imidazole. Bound proteins were eluted with cell lysis buffer
containing 250 mM imidazole, and then imidazole was removed by
dialysis into PBS.
RDH10 activity assays with RBP1
The pcDNA6-RDH10 expression vector was transfected into COS1
cells using FuGENE 6 reagent. At 48 h after transfection, cells were
lysed by sonication in RDH activity buffer. The cell lysate was
centrifuged at 100,000×g for 1 h to separate the cytosolic and
membrane fractions. The supernatant was removed, and the pellet
was resuspended in RDH activity buffer and brieﬂy centrifuged at
18,000×g to wash away remaining cytosolic proteins. The ﬁnal
membrane fraction was resuspended in RDH activity buffer, analyzed
for protein concentration by Bradford analysis, and stored at−80 °C.
Under dim red light, a total of 32 μg of membrane proteins were
suspended in a ﬁnal volume of 200 μl of RDH activity buffer containing
1% BSA and 1 mM NADP+ in the absence or presence of increasing
concentrations of puriﬁed recombinant RBP1-His. The reaction
was initiated by adding 2 μl of atROL dissolved in DMF at a ﬁnal
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37 °C for 30 minwith gentle agitation. The reactionwas terminated by
the addition of 300 μl of methanol, and retinoids were extracted with
300 μl of hexane for HPLC analysis using a normal phase 5 μm column
(Lichrosphere SI-60; Alltech, Deerﬁeld, IL) (Wu et al., 2004). The
enzymatic activity was calculated from the area of the atRAL peak
using synthetic puriﬁed atRAL as standard for calibration with
Empower software.
ADH7 activity assays
COS1 cells were transfected with pcDNA3.1-Flag-ADH7 expression
vector using FuGENE 6 reagent. At 48 h post-transfection, cells were
lysed in RDH activity buffer by 5 cycles of freeze-thawing, and then
cytosolic fractions were prepared by centrifuging at 18,000×g for
10 min. The pellets were discarded, and the supernatant (cytosolic
fraction) was analyzed for protein concentration by Bradford analysis,
and stored at −80 °C.
Under dim red light, a total of 0.7 μg of cytosolic proteins were
suspended in a ﬁnal volume of 200 μl of RDH activity buffer containing
1% BSA, and 1 mM NAD+. The reaction was initiated by adding either
2 μl of either atROL dissolved in DMF or atROL incorporated into
liposomes, both at a ﬁnal concentration of 5.5 μM atROL in the
reaction. The reaction mixtures were incubated at 37 °C with gentle
agitation for the speciﬁed incubation periods. The reactions were
terminated by the addition of 300 μl of methanol, and retinoids were
extracted and analyzed by HPLC as described above for RDH10 activity
assays.
Results
RDH10 is only necessary for the ﬁrst step of embryonic atRA synthesis
The developmental importance of resolving the precise role of
RDH10 in embryonic atRA synthesis is highlighted by the observations
that widely expressed ADHs do not compensate for the loss of RDH10
in Rdh10trex mutants (Sandell et al., 2007), and that developing
embryos have RALDH-independent sites of atRA synthesis (Mic et al.,
2002; Niederreither et al., 2002b). We therefore tested the capacity of
RDH10 to catalyze the second oxidation of atRAL to atRA in vitro.
Recombinant RDH10 was expressed in COS1 cells, and cell lysates
were prepared to assay RDH10 activity with atRAL substrate and
either NAD+ or NADP+ cofactor. Neither untransfected nor RDH10-
expressing cell lysates produced any detectable atRA (Figs. 1A and B).
In contrast, cell lysates expressing recombinant RALDH2 produced a
signiﬁcant amount of atRA under the same conditions. These data
indicate that as anticipated RDH10 lacks the ability to oxidize atRAL in
vitro and is therefore not likely involved in the second oxidative step
of atRA synthesis.
To address the question of whether the essential contribution of
RDH10 to embryonic atRA synthesis is limited to the oxidization of
atROL to atRAL, thus providing a substrate for RALDH enzymes, we
tested if supplementation of thematernal dietwith atRAL could prevent
developmentalmalformations in Rdh10trex embryos. Following atRAL or
mock diet supplementation, embryos were collected at E12.5 and
histological analysis was performed to evaluate the morphological
development of the lungs, liver, forelimbs and craniofacial anatomy.
Rdh10trex embryos typically exhibit amidline facial cleftwith agenesis of
the nasal septumand nasal cavity (Fig. 1C). The eyes aremalformed and
submergedwithin head tissues (Fig. 1C). More caudally, there is little to
no evidence for lung bud formation and growth, and the liver is
hypoplastic (Fig. 1F). The forelimbs are always truncated with ulna
agenesis (Fig. 1I). Comparisons with wild-type embryos (Figs. 1D,G,J)
demonstrate that atRAL supplementation to a large extent rescues the
lung, liver, forelimb, and craniofacial abnormalities that are otherwise
present inmock-rescued Rdh10trex embryos supplementedwith corn oilalone (Figs. 1C–K). Rescued embryos (Figs. 1E,H,K) exhibit a clear nasal
septum in the midline of the face, ﬂanked bilaterally by well developed
nasal cavities and the eyes are no longer occluded within head
mesenchyme (Fig. 1E). The atRAL supplementation rescued lung bud
induction and growth of both the lungs and liver (Fig. 1H). Forelimb
development and patterning were also restored. Not only were the
forelimbs in rescued embryos equivalent in size to controls, but agenesis
of the ulna was prevented (Fig. 1K). The ﬁnding that atRAL supplemen-
tation is sufﬁcient to restore development in Rdh10trex embryos
establishes that the essential role of RDH10 during embryogenesis is
in catalysis of the ﬁrst step of Vitamin Ametabolism and atRA synthesis.
This disproves the previously accepted theory that the tissue speciﬁcity
of atRA synthesis from atROL is dictated solely by RALDH activity
(Duester et al., 2003; Molotkov et al., 2002). Both RDH and RALDH
activities are critical for the spatiotemporalmetabolismofVitaminAand
generationof atRA. Furthermoreour results demonstrate that there is an
absence of widespread, redundant RDH activity in the developing
embryo, despite the widespread expression of ADHs.
We extended atRAL supplementation for the remainder of
gestation, which rescued Rdh10trex mutants to birth (Figs. 2A and B).
The size of Rdh10trex pups appeared normal, however they died
shortly thereafter. Despite evidence for normal eye, limb and lung
development and growth, as well as proper nasal cavity formation and
the absence of facial clefting during embryogenesis, it is apparent that
postnatally the lungs never inﬂate (Figs. 2C–F). It is unclear why
Rdh10trex pups do not breathe and fail to survive, but it is likely a
consequence of incomplete nasal slit formation and connection to the
nasal cavity or alternatively a problem in diaphragm development.
These residual phenotypes reﬂect the challenges of dietary supple-
mentation regimes in rescuing developmental anomalies and result
from variations in dosage or tissue distribution of supplemental atRAL
relative to endogenously produced atRAL.
RDH10 accounts for the majority of embryonic RDH activity
To understand why enzymes with RDH activity cannot fully
compensate for the loss of RDH10 during embryogenesis, we
evaluated the contribution of RDH10 to total embryonic RDH activity.
In Rdh10trex embryos, RDH10 protein was not detected at any of the
developmental stages examined (Fig. 3A), indicating that the point
mutation in the Rdh10trex allele severely reduces RDH10 protein
stability to undetectable levels. Thus, we compared the RDH activity of
Rdh10trex embryos to wild-type embryos to determine the contribu-
tion of RDH10 to total embryonic RDH activity. Embryonic whole cell
lysates had very little RDH activity, due to the neutralizing effects of
reducing factors in the cytosol (data not shown). Therefore, to
measure membrane-bound RDH activity in the absence of cytosolic
factors, membrane fractions were prepared from whole embryos.
Membrane fractions displayed RDH activity with both NAD+ and
NADP+ cofactors, although NADP+-dependent RDH activity was 2 to
8-fold higher than NAD+-dependent activity, which indicates that the
majority of membrane-bound RDH activity is NADP+-dependent
(Figs. 3B and C). Rdh10trexmutants have a signiﬁcant reduction in RDH
activity from E9 to E13 compared to wild type. The most sizeable
difference occurs in NADP+-dependent RDH activity at E12 and E13,
the stage at which wild-type embryos have the highest level of
activity, while in contrast Rdh10trex embryos have nearly undetectable
activity (Fig. 3B). We have previously shown that RDH10 prefers
NADP+ cofactor in vitro (Wu et al., 2002, 2004), which explains why
NADP+-dependent activity is severely reduced in Rdh10trex mice.
These data demonstrate that RDH10 accounts for the majority of
membrane-bound RDH activity in the developing embryo.
Consistent with our previous study, we show that a small amount
of microsomal RDH activity remains in Rdh10trex mutant embryos
from E9 to E11 (Figs. 3B and C). This residual RDH activity could be
due to a small amount of persistent RDH10 activity stemming from
Fig. 1. RDH10 is strictly required for the ﬁrst step of embryonic atRA synthesis. (A) Western blot of COS1 whole cell lysates shows expression of either RDH10 or RALDH2-His
following transfection (UNTF, untransfected cells). (B) COS1 whole cell lysates shown in (A) were used for in vitro atRAL oxidation assays. The graph shows the amount of atRA
generated from each cell lysate and represents the mean+/−s.d. from three independent experiments. (C–K) Embryos were collected at E12.5. The left (C, F, I) and middle (D, G, J)
columns show embryos processed after mock supplementation which are either Rdh10trex or wild type, respectively. The right column (E, H, K) shows Rdh10trex embryos processed
after maternal supplementation with all-trans-retinal. H&E-stained transverse sections are shown at the level of: (C–E) the frontonasal process, dorsal top, ventral bottom. (ns, nasal
septum; nc, nasal cavity); (F–H) the liver and lung bud, dorsal right, ventral left. (liv, liver; rlu, right lung bud; llu, left lung bud). (I–K) Alcian blue cartilage staining of forelimbs
(h, humerus; r, radius; u, ulna). These histological analyses show that atRAL supplementation is sufﬁcient to rescue craniofacial, lung, liver and forelimb development in Rdh10trex
embryos.
351K.M. Farjo et al. / Developmental Biology 357 (2011) 347–355the presence of a low level of RDH10 protein that is beyond the limits
of detection by immunoblotting. Alternatively, the residual RDH
activity may be due to the function of one or more other membrane-bound RDHs, the identity of which is unknown. Interestingly, RDH10-
independent activity is completely absent at E12 and E13, indicating
that RDH10 is the only membrane-bound RDH expressed during this
Fig. 2. atRAL supplementation rescues Rdh10trex mutants to birth. Pregnant females were supplemented with atRAL by oral gavage every 12 h as described in material and methods,
beginning at E7.25 and extending up until birth. (A and B) Pups were collected and photographed directly after birth. (C-F) H&E-stained transverse sections through the lung
tissue are shown at 10× (C and D) and 40× (E and F) magniﬁcation. Note the expanded lung tissue morphology, indicative of lung inﬂation, in the Rdh10+/trex pup. In contrast, the
Rdh10trex/trex lung tissue remains condensed.
352 K.M. Farjo et al. / Developmental Biology 357 (2011) 347–355stage of development, which may account for the timely death of
Rdh10trex embryos at E12.5/E13. These results strongly suggest that
RDH10 is essential for embryonic RDH activity, not simply because itgenerates pools of atRAL in speciﬁc tissues, but rather because it
accounts for the majority of the RDH activity throughout the
developing embryo. In contrast to previous dogma, these data show
Fig. 3. Rdh10trex embryos have a signiﬁcant reduction in total RDH activity. (A) Whole embryo membrane fractions were prepared for RDH activity assays and analyzed by Western
blotting (20 μg of protein per lane) using an anti-RDH10 antibody and an anti-pan-cadherin antibody as a loading control. (B and C) RDH activity was measured with either (B)
NADP+ or (C) NAD+ cofactor. The bar graphs represent the mean+/−s.d. from at least three independent experiments (*pb0.05 by two-way ANOVA).
Fig. 4. RDH10 does not utilize holo-RBP1 as substrate. (A) Western blotting with an anti-
RBP1 antibody was performed on whole embryo homogenates (50 μg protein per lane)
from stages E9 to E16. RBP1 expression was detected at all developmental stages form E9
toE16. (BandC)RecombinantHis-RBP1was expressed inE. coliand thenpuriﬁedbynickel
afﬁnity chromatography for use in in vitro RDH activity assays. (B) Puriﬁed His-RBP1
(2.5 μg in lane 1 and 5 μg in lane 2) was analyzed byWestern blotting using an anti-RBP1
antibody. (C) The purity of theHis-RBP1was evaluated by Coomassie staining. Lanes 1 and
2 were loaded with 5 μg and 10 μg of puriﬁed His-RBP1, respectively. (D) RDH activity
assays were performed with atROL substrate in the absence or presence of increasing
concentrations of either puriﬁed recombinant His-RBP1 or His-KBP (non-retinoid-binding
protein, negative control). The graph represents the mean+/−s.d. from at least three
independent experiments (*pb0.05 by Student's t-test analysis).
353K.M. Farjo et al. / Developmental Biology 357 (2011) 347–355that an NADP+-dependent membrane-bound RDH10 is the primary
embryonic RDH, whereas NAD+-dependent cytosolic ADHs do not
contribute signiﬁcantly to embryonic RDH activity.
Holo-RBP1 is not a substrate for RDH10
Cellular retinol-binding protein (RBP1) is a cytosolic proteinwhich
binds to atROL with high afﬁnity and speciﬁcity (MacDonald and Ong,
1987; Noy, 2000). Consequently, it has been proposed that physio-
logically relevant RDHs must be able to utilize holo-RBP1 as substrate,
yet all RDHs studied to date lack the ability to efﬁciently oxidize holo-
RBP1 (Belyaeva et al., 2005; Belyaeva et al., 2008; Gallego et al., 2006;
Kedishvili et al., 1998; Napoli, 1999). We performed immunoblotting
on whole embryo homogenates and found that RBP1 is expressed as
early as E9 and up to E16 (Fig. 4A). This demonstrates that RBP1
expression coincides temporally with RDH10 expression (Fig. 3A) and
ongoing embryonic atRA synthesis. This also suggests that RDH10
must be able to function in the presence of RBP1.
To determine if RDH10 can oxidize atROL from holo-RBP1, RDH10
activity was measured in vitro with increasing concentrations of
puriﬁed recombinant His-tagged RBP1 (Figs. 4B and C). As a negative
control, the assay was performed with a puriﬁed recombinant His-
tagged protein that does not bind to retinoids, kallikrein-binding
protein (KBP). At a 1:1 molar ratio of RBP1 to atROL, atRAL production
was reduced to 22% of the amount of atRAL produced in the absence of
RBP1, and at a 2:1molar ratio of RBP1:atROL only 5% activity remained
(Fig. 4D). This remaining RDH10 activity is due to dissociated free
atROL which is in equilibrium with RBP1, and is consistent with a
recently published report (Belyaeva et al., 2008). In contrast, non-
speciﬁc inhibition by KBP only reduced RDH10 activity to 90% of its
normal level, even at a 5:1 molar ratio of KBP:atROL. These data
demonstrate that RBP1 inhibits RDH10 activity, and thus RDH10 does
not utilize holo-RBP1 as substrate.
ADH7 cannot efﬁciently oxidize atROL from phospholipid membranes
RDH10 is a membrane-bound protein, and we have previously
shown that binding to membrane is essential for RDH10 activity
(Takahashi et al., 2009). The substrate atROL is a relatively hydrophobic
molecule, which is localized in cellularmembranes in vivo (Noy and Xu,
1990). Binding to RBP1 provides atROL with a hydrophobic binding
pocket within the aqueous cytosolic compartment, but it does not
354 K.M. Farjo et al. / Developmental Biology 357 (2011) 347–355preclude accumulation of RBP1-free atROL in cellular membranes. We
speculate that cellular membranes contain a pool of RBP1-free atROL
which allowsmembrane-bound RDH10 to oxidize atROL in vivo, despite
the cytosolic expressionof RBP1.Wehypothesize that cytosolicADHsdo
not contribute signiﬁcantly to embryonic RDHactivity because cytosolic
atROL is in the form of holo-RBP1, which inhibits ADH activity, and
ADHs have limited access to the RBP1-free pools of atROL in cellular
membranes.
To test this theory, wemeasured recombinant ADH7 activity in vitro
using equimolar concentrations of either atROL in aqueous solution or
atROL incorporated into phospholipid membranes (liposomes) as
substrate. With increasing reaction time, ADH7 generated increasing
amounts of atRAL when provided with atROL in aqueous solution
(Fig. 5B). In contrast, atRAL generationwas undetectable over the entire
incubation periodwhenADH7was providedwith an equimolar amount
of atROL incorporated in liposomes. This demonstrates that ADH7 has
limited access to atROL localized in membranes, and supports the idea
thatADHsareunable to compensate for the lossof RDH10becauseADHs
have limited access to RBP1-free atROL in cellular membranes.
Discussion
Retinoic acid is a potent signaling molecule necessary for
patterning, morphogenesis, and organogenesis during embryonic
development. Retinoic acid is synthesized from Vitamin A (all-trans-
retinol; atROL) via a two-step oxidation process, and our results
clearly demonstrate that the ﬁrst and second enzymatic steps of
embryonic Vitamin A metabolism and atRA synthesis are largely
conﬁned to separate cellular compartments. This may play a critical
role in regulating the precise spatiotemporal control of retinoic acid
synthesis during embryogenesis, which is important because both
excessive and insufﬁcient atRA signaling can result in congenital
abnormalities and fetal death.
Although the RALDH enzymes responsible for the second oxidation
reaction of atRAL to atRA have been deﬁnitively known for some time,
the identity of the enzymes essential for the ﬁrst oxidation reaction of
Vitamin A (atROL) to atRAL during embryogenesis have remained
elusive. Our study reveals that membrane-bound RDH10 is the primaryFig. 5. ADH7 cannot efﬁciently oxidize atROL from liposomal membranes. (A) Western
blot of COS1 cell lysates shows expression of Flag-ADH7 following transfection. (B) ADH7
activity was quantiﬁed using either atROL in aqueous solution or atROL incorporated into
liposomes as substrate. The graph represents the mean+/−s.d. from at least three
independent experiments.embryonic RDH essential for the oxidation of atROL during the
generation of atRA in the developing embryo. Furthermore we
demonstrated that the membrane localization of RDH10 is functionally
important to allow RDH10 to oxidize RBP1-free pools of atROL stored in
the cellular membrane. This explains why widely expressed cytosolic
ADHs cannot compensate for the loss of RDH10, because RBP1 inhibits
oxidation of cytosolic pools of atROL andADHs cannot efﬁciently extract
and oxidize RBP1-free atROL from membranes.
Our present study, combined with previous studies showing ADH-
deﬁcient mice develop normally unless reared under conditions of
either Vitamin A deﬁciency or excess, strongly suggests that cytosolic
ADHs do not contribute signiﬁcantly to the oxidation of atROL during
normal embryonic development. However, ADHsmay be important in
the event of gestational exposure to excessive levels of either atROL or
ethanol, both of which can be toxic in high doses. This theory is
supported by previous studies which have shown that Adh1−/− and
Adh4−/− mice have delayed metabolic clearance of excess doses of
atROL and ethanol (Deltour et al., 1999a,b). Since cytosolic RBP1 binds
atROL at a 1:1 molar ratio, excessive levels of atROL that are in molar
excess of RBP1 may limit RBP1-mediated inhibition of ADH activity
and thereby increase ADH-mediated oxidation of atROL under such
circumstances. It will be interesting in future studies to test this
genetically in Rdh10/Adh compound mutants.
Conclusions
In summary, this study reveals that membrane-bound RDH10 is the
primary embryonic RDH essential for atRA generation in the developing
embryo, and that the ﬁrst and second enzymatic steps of embryonic
atRA synthesis are largely conﬁned to separate cellular compartments.
Membrane localizationof RDH10 is important toallowRDH10 to oxidize
RBP1-free pools of atROL stored in the cellular membrane. Widely
expressed cytosolic ADHs cannot compensate for the loss of RDH10,
because RBP1 inhibits oxidation of cytosolic pools of atROL and ADHs
cannot efﬁciently extract andoxidizeRBP1-freeatROL frommembranes.
These breakthrough studies provide a foundation for expanding our
understanding of the cellular mechanisms which modulate atRA
metabolism and signaling during embryogenesis.
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